SOAT1 and systemic lupus erythematosus: With this respect, clinical trials blocking type-I IFN signaling through the IFN receptor or the JAK/STAT signaling pathway are already underway in SLE to reduce autoimmune inflammation (71, 72), which could also prevent atherosclerosis progression in patients.